MedTrace Logo

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

NCT03227042 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2022-10-26

No results posted yet for this study

Summary

This is a natural history study for children up to 18 years of age who have been diagnosed with Mucopolysaccharidosis Type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B). Mucopolysaccharidosis type IIIB is a severe neurodegenerative disorder. The information gathered from this trial may help inform the design and interpretation of subsequent interventional studies. No clinical intervention or study drug is provided by Allievex in this study.

Conditions

  • Mucopolysaccharidosis Type IIIB

Sponsors & Collaborators

  • Allievex Corporation

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Allievex Medical Monitor

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-16
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Colombia
  • Germany
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03227042 on ClinicalTrials.gov